Session | Hemorrhagic fevers

Session | Hemorrhagic fevers

🎙 Epicentre - MSF 👥 737 📅 June 15, 2026 ⏱ 34 min 👁 18 📄 expert opinion 🧭 2026-08-16
Available in: English (current) Français

Keywords

EbolaLassa fevertransmissioncontact tracingvaccination

Summary

This session from Epicentre/MSF focuses on hemorrhagic fevers, primarily Ebola and Lassa fever. The first speaker, Rebecca, provides an overview of Epicentre’s historical involvement in Ebola outbreaks since 1995, highlighting contributions to surveillance, vaccine trials (rVSV-ZEBOV and Ad26/MVA), and the PALM trial that identified effective monoclonal antibody treatments. She emphasizes the disproportionate impact on healthcare workers and caregivers, and the importance of community trust. The second speaker, Hugo, presents a detailed analysis of Ebola transmission using chains of transmission from the 10th DRC outbreak (2018-2020). He quantifies transmission heterogeneity (80% of cases infected by 18% of cases), the impact of response measures (isolation, contact tracing, vaccination) in reducing secondary cases, and the negative effect of security incidents and community mistrust on outbreak control. The session concludes with a Q&A discussing post-mortem transmission and the value of forward contact tracing.

139 words

Critical Evaluation

Value of the Information & Strength of the Argument

The video provides valuable insights into the epidemiology and control of hemorrhagic fevers, particularly Ebola. The argumentation is solid, based on data from a large outbreak and peer-reviewed research. The speakers clearly explain complex concepts like transmission heterogeneity and the effectiveness of response measures. The value lies in the practical, field-based perspective from MSF, highlighting challenges and successes in real-world settings. The argumentation is logical and supported by quantitative evidence, though some claims could benefit from more detailed citations.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, with references to published studies and data from the 10th DRC outbreak. The sources are credible, coming from Epicentre/MSF and collaborations with WHO and African institutions. The title is somewhat generic but accurately reflects the content. The presentation is well-structured and evidence-based, though it is a conference session rather than a formal publication. The adéquation between title and content is good.

160 words

Title / Content Match

The title 'Session | Hemorrhagic fevers' is broad but accurately reflects the content, which covers Ebola and Lassa fever.

Quality & Reliability

8/10

The video features expert speakers from Epicentre/MSF with extensive field experience, presenting data from peer-reviewed research (e.g., the 10th DRC Ebola outbreak analysis). The content is scientifically grounded, with clear methodology and references to published studies. However, it is a conference session, not a formal peer-reviewed publication, and some claims lack detailed citations.

Key Moments

Cited Sources

  • Epicentre - MSF — Organization's official website, providing context on their research and activities.

Concurring Sources

  • Ebola virus disease - WHO — WHO fact sheet confirming key facts about Ebola transmission and control.
  • Lassa fever - WHO — WHO fact sheet providing information on Lassa fever, consistent with the video's claims.

Contribution & Novelties

The video provides a comprehensive overview of Epicentre’s contributions to hemorrhagic fever research, with a novel analysis of Ebola transmission heterogeneity from the 10th DRC outbreak. It quantifies the impact of response measures and highlights the importance of community trust. The presentation offers practical insights for outbreak response.

Pour aller plus loin :

  • Ebola virus disease - WHO — Official WHO fact sheet on Ebola, providing background and current information.
  • Lassa fever - WHO — Official WHO fact sheet on Lassa fever, covering transmission and prevention.
  • Ring vaccination trial for Ebola - PubMed — Original publication of the rVSV-ZEBOV ring vaccination trial, a key reference for vaccine efficacy.
  • PALM trial results - NEJM — Publication of the PALM trial, demonstrating efficacy of monoclonal antibodies for Ebola.
  • Transmission heterogeneity of Ebola - Science — Study on transmission heterogeneity in the West African Ebola outbreak, relevant to the analysis presented.

148 words

Radar Profile

The radar profile shows high scores in information quality and reliability, with slightly lower scores in technical level and quantity, reflecting a balance between expert depth and accessibility. The video is strong in providing credible, well-sourced information, making it a valuable resource for understanding hemorrhagic fever epidemiology.

Reliability 8/10